AbbVie (ABBV) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

AbbVie

NYSE•Healthcare•Drug Manufacturers - General

$264.02+1.51(0.01%)After hours

Market Cap

$467.05B

P/E

74.0x

P/S

7.3x

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

How this company scores

WeakMetricSide Score: 70/100

Grade capped at D — Negative equity — the balance sheet is insolvent. Strongest: Growth (23/25); weakest: Balance Sheet & Red Flags (12/25).

Profitability17/25

Growth23/25

Balance Sheet & Red Flags12/25

Cash & Earnings Quality18/25

Strengths

Strong marginsRising earningsInterest easily coveredCash-backed earnings

Grade capped at D

Negative equity — the balance sheet is insolvent.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 74.0x5y range 18.9x – 165.3x

Currently above its 20-quarter median.

P/S · 7.3x5y range 3.5x – 7.3x

Currently above its 20-quarter median.

P/B · 260.9x5y range 14.2x – 260.9x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Leverage Risk

Red Flag

D/E ratio is 45.4 — heavily leveraged and vulnerable to rising rates or cash flow dips.

Price & Volume

Market Cap $467.05B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $64.39B
Q. Revenue: $16.99B
TTM EBITDA: $24.74B
TTM Op. Income: $16.87B
Q. Op. Income: $6.43B
TTM Net Income: $6.31B
Q. Net Income: $3.61B
EPS: $2.04
Shares Out.: $1.77B

$64.39B in TTM revenue grew 10.4% YoY, reaching $16.99B last quarter. TTM EBITDA of $24.74B and TTM operating income of $16.87B show growth is flowing through to the bottom line. TTM net income of $6.31B means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 74.7%
EBITDA Margin: 48.9%
Op. Margin: 37.9%
Net Margin: 21.3%

Op. margin of 37.9% is up 6.1% YoY — cost efficiency is improving. Net margin at 21.3% and gross margin of 74.7% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 19% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 74.0x
P/S Ratio: 7.3x
P/B Ratio: N/A

At 74.0x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 7.3x and P/B of 0.0x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Over the past year, P/E is down 15% — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $135.12B
Cash: $6.57B
Long-Term Debt: $62.48B
Book Value: $-5.93B
D/E Ratio: N/A
Debt/EBITDA: 7.5

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $3.44B
TTM Free Cash Flow: $18.21B
FCF Margin: 28.3%
FCF / Net Income: 2.9

TTM FCF of $18.21B on $3.44B in operating cash flow. The FCF / Net Income ratio of 2.9x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is down 0% — a weakening trend.